Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is Enrolling in a Phase 1 Clinical Trial Tonix is Developing TNX-1500 for Prevention of Kidney Allograft Rejection as the First Indication: Multiple Other Indications, including Autoimmune Disorders, are Planned CHATHAM, N.J., Oct.

由马萨诸塞州总医院移植科学中心指导的研究TNX-1500正在参加第一阶段临床试验Tonix正在开发TNX-1500，用于预防同种异体肾移植排斥反应，作为第一个适应症：包括自身免疫性疾病在内的多种其他适应症正在计划中查塔姆，新泽西州，Oct。

18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.

182023年（GLOBE NEWSWIRE）-Tonix Pharmaceuticals Holding Corp.（纳斯达克股票代码：TNXP）（Tonix或该公司），一家拥有销售产品和开发候选人渠道的生物制药公司，今天宣布在该杂志上发表一项研究Nature1由马萨诸塞州总医院（MGH）移植科学中心的教师与生物技术公司合作，eGenesis，利用TNX-1500（Fc修饰的二聚体抗CD40L单克隆抗体[mAb]）作为免疫调节方案的一部分，以防止器官移植排斥。

Tonix’s TNX-1500 is in development for the prevention of human kidney organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. TNX-1500 was invented and developed in-house by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, and colleagues.

Tonix的TNX-1500正在开发中，用于预防人体肾脏器官移植排斥反应。TNX-1500的分子靶标是CD40配体（CD40L），也称为CD154。TNX-1500由Tonix Pharmaceuticals的首席执行官Seth Lederman及其同事在内部发明和开发。

TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to decrease FcγRII binding and to reduce the potential for thrombosis. Preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated.

TNX-1500是第三代抗CD40L单克隆抗体，已通过蛋白质工程设计，可降低FcγRII结合并降低血栓形成的可能性。非人类灵长类动物的临床前研究表明，TNX-1500在预防同种异体移植物和异种移植器官排斥方面显示出活性，并且耐受性良好。

The research in the Nature paper was conducted at MGH, led by principal investigator Tatsuo Kawai, M.D., Professor of Surgery, Harvard Medical School and the Center for Transplantation Science. A “News and Views” editorial2 and .

Nature论文的研究是在MGH进行的，由首席研究员Tatsuo Kawai，医学博士，哈佛医学院外科教授和移植科学中心领导。“新闻与观点”社论2和。